Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume

Journal of Radiation Research

Volumn 55, Issue 5, 2014, Pages 988-995

  Takeda, Atsuya ^a   Oku, Yohei ^a   Sanuki, Naoko ^a   Eriguchi, Takahisa ^a   Aoki, Yousuke ^a   Enomoto, Tatsuji ^a   Kaneko, Takeshi ^a,b   Nishimura, Shuichi ^a   Kunieda, Etsuo ^c  

^a OFUNA CHUO HOSPITAL   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

dose escalation study; homogeneity index; lung cancer; Phase I study; prescription dose; stereotactic body ridiotherapy

Indexed keywords

BIOLOGICAL ORGANS; TOXICITY; TUMORS; VOLUMETRIC ANALYSIS;

DOSE-ESCALATION STUDY; HOMOGENEITY INDEX; LUNG CANCER; LUNG TUMOR; PHASE I; PHASE I STUDY; PRESCRIPTION DOSE; RADIATION PNEUMONITIS; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC BODY RIDIOTHERAPY;

RADIOTHERAPY;

ADVERSE EFFECTS; AGED; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; HUMAN; LUNG NEOPLASMS; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PROCEDURES; RADIATION DOSE FRACTIONATION; RADIATION INJURIES; RADIOSURGERY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR VOLUME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DOSE FRACTIONATION; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; RADIATION INJURIES; RADIOSURGERY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84908205314     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1093/jrr/rru037     Document Type: Article

References (36)

1. Ettinger DS, Akerley W, Borghaei H et al. NCCN Clinical Practice Guidelines in Oncology website. Non-small cell lung cancer, version 2.2013. National Comprehensive Cancer Network, 2013. http://www.nccn.org/professionals/physician- gls/f-guidelines.asp (13 September 2013, date last accessed).
2. Takeda A, Kunieda E, Ohashi T et al. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol 2011;101:255-9.
3. Norihisa Y, Nagata Y, Takayama K et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys 2008;72:398-403.
4. Takeda A, Kunieda E, Sanuki N et al. Dose distribution analysis in stereotactic body radiotherapy using dynamic conformal multiple arc therapy. Int J Radiat Oncol Biol Phys 2009;74:363-9.
5. Takeda A, Sanuki N, Kunieda E et al. Stereotactic body radi otherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys 2009;73:442-8.
6. Takeda A, Yokosuka N, Ohashi T et al. The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT). Radioth er Oncol 2011;101:291-7.
7. Allibhai Z, Taremi M, Bezjak A et al. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lun g cancer. Int J Radiat Oncol Biol Phys 2013;87:1064-70.
8. Onishi H, Shirato H, Nagata Y et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: upd ated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2:S94-100.
9. Oku Y, Takeda A, Kunieda E et al. Analysis of suitable prescribed isodose line fitting to planning target volume in stereotactic body radiotherapy using dynamic conformal multiple arc therapy. Pract Radiat Oncol 2011;2:46-53.
10. Benedict SH, Yenice KM, Followill D et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010;37:4078-101.
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumo rs. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
12. Takeda A, Ohashi T, Kunieda E et al. Comparison of clinical, tumour-related and dosimetric factors in grade 0-1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours. Br J Radiol 2012;85: 636-42.
13. Fakiris AJ, McGarry RC, Yiannoutsos CT et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009;75:677-82.
14. Palma DA, Senan S, Tsujino K et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international indi vidual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013;85:444-50.
15. Mehta V., Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention, Int J Radiat Oncol Biol Phys, 2005, 63, 5-24.
16. Matsuo Y, Shibuya K, Nakamura M et al. Dose-volume metrics associated with radiation pneumonitis after stereotactic body radiation therap y for lung cancer. Int J Radiat Oncol Biol Phys 2012;83:e545-9.
17. Barriger RB, Forquer JA, Brabham JG et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients t reated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2012;82:457-62.
18. Fujino M, Shirato H, Onishi H et al. Characteristics of patients who developed radiation pneumon itis requiring steroid therapy after stereotactic irradiation for lung tumors. Cancer J 2006;12:41-6.
19. Ogo E, Komaki R, Fujimoto K et al. A survey of radiationinduced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy in Japan. Int J Radiat Oncol Biol Phys 2008;71:123-31.
20. Katayama N, Sato S, Katsui K et al. Analysis of factors associated with ra diation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy. Int J Radiat Oncol Biol Phys 2009;73:1049-54.
21. Murai T, Shibamoto Y, Nishiyama T et al. Organizing pneumonia after stereotactic ablative radiotherapy of the lung. Radiat Oncol 2012;7:123.
22. Dunlap NE, Cai J, Biedermann GB et al. Chest wall volume receiving 30 Gy predicts risk o f severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010;76:796-801.
23. Mutter RW, Liu F, Abreu A et al. Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer. Int J Radiat Oncol Biol Phys 2012;82:1783-90.
24. Creach KM, El Naqa I, Bradley JD et al. Dosimetric predictors of chest wall pain after lung stereotactic body radiotherapy. Radiother Oncol 2012;104:23-7.
25. Hoppe BS, Laser B, Kowalski AV et al. Acute skin toxicity following stereotactic body radiat ion therapy for stage I non-small-cell lung cancer: who's at risk? Int J Radiat Oncol Biol Phys 2008;72:1283-6.
26. Le QT, Loo BW, Ho A et al. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol 2006;1:802-9.
27. Timmerman R , Papiez L, McGarry Ret al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003;124:1946-55.
28. Ernst-Stecken A, Lambrecht U, Mueller R et al. Hypofractionated stereotactic radiotherapy for primary and secondary intrapulmonary tumors: first results of a phase I/II study. Strahlenther Onkol 2006;182:696-702.
29. Timmerman R, McGarry R, Yiannoutsos C et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;2 4:4833-9.
30. Nagata Y, Matsuo Y, Takayama K et al. Current status of stereotactic body radiotherapy for lung cancer. Int J Clin Oncol 2007;12:3-7.
31. Senan S, L agerwaard F. Stereotactic radiotherapy for stage I lung cancer: current results and new developments. Cancer Radiother 2010;14:115-8.
32. Zhang J, Yang F, Li B et al. Which is the optimal b iologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 2011;81:e305-16.
33. van Baardwijk A, Tome WA, van Elmpt W et al. Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiother Oncol 2012;105:145-9.
34. McCammon R, Schefter TE, Gaspar LE et al. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2009;73:112-8.
35. Shirata Y, Jingu K, Koto M et al. Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis. Radiat Oncol 2012;7:182.
36. Dunlap NE, Larner JM, Read PW et al. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT). J Thorac Cardiovasc Surg 2010 ;140:583-9.